Clinical Features and Patient Outcomes of Hidradenitis Suppurativa: A Cross-Sectional Retrospective Study
Overview
General Surgery
Authors
Affiliations
Background: Despite the high burden of disease associated with hidradenitis suppurativa (HS), epidemiologic data are scarce.
Objective: The objective was to review demographic features and clinical findings in 80 HS patients from 2 referral centres in Ontario, Canada, from October 2013 to September 2014, and to assess for factors that are associated with more advanced disease.
Methods: Multicentre cross-sectional study. The data on demographic and clinical features were obtained by questionnaires and chart review.
Results: Of a total of 80 patients (67.5% females), percentages of patients in Hurley stages I, II, and III were 15.4%, 55.8%, and 28.9%, respectively. Most patients were not diagnosed for more than 1 year (70.1%). Patients with more severe disease were more likely to be females and to have a greater number of lesions and were less likely to be diagnosed initially by a dermatologist.
Conclusions: This study documents the common demographic and clinical features of HS to optimize resource allocation and patient outcomes.
Comorbidities, Clinical Presentation, Subtypes, and Treatment of HS Patients in Lithuania.
Raudonis T, Sakaityte A, Vileikis T, Cernel V, Ganceviciene R, Zouboulis C J Clin Med. 2024; 13(13).
PMID: 38999466 PMC: 11242771. DOI: 10.3390/jcm13133900.
Hammud A, Avitan-Hersh E, Khamaysi Z J Clin Med. 2023; 12(12).
PMID: 37373616 PMC: 10299265. DOI: 10.3390/jcm12123921.
Optic neuropathy in a patient treated with adalimumab for hidradenitis suppurativa.
Alnaif S, Thakur S, Griffey P, Pariser R JAAD Case Rep. 2023; 37:85-88.
PMID: 37342403 PMC: 10277285. DOI: 10.1016/j.jdcr.2023.05.022.
Management of axillary hidradenitis suppurativa: A case report.
AlQahtani S Int J Health Sci (Qassim). 2023; 17(1):61-64.
PMID: 36704493 PMC: 9832907.
Shirah B, Shirah H J Cutan Aesthet Surg. 2017; 10(2):95-100.
PMID: 28852296 PMC: 5561718. DOI: 10.4103/JCAS.JCAS_80_16.